BRPI0413018A - composto, e, método para tratar ou prevenir doenças auto-imunes e/ou um ou mais sintomas associados com eles - Google Patents
composto, e, método para tratar ou prevenir doenças auto-imunes e/ou um ou mais sintomas associados com elesInfo
- Publication number
- BRPI0413018A BRPI0413018A BRPI0413018-9A BRPI0413018A BRPI0413018A BR PI0413018 A BRPI0413018 A BR PI0413018A BR PI0413018 A BRPI0413018 A BR PI0413018A BR PI0413018 A BRPI0413018 A BR PI0413018A
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- autoimmune diseases
- compound
- symptoms
- symptoms associated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
"COMPOSTO, E, MéTODO PARA TRATAR OU PREVENIR DOENçAS AUTO-IMUNES E/OU UM OU MAIS SINTOMAS ASSOCIADOS COM ELES". A presente invenção promove métodos para tratar ou prevenir doenças auto-imunes com compostos de 2,4-diamino-pirimidina, assim como também, métodos para tratar, prevenir ou aliviar sintomas associados com tais doenças. Os exemplos específicos das doenças auto-imunes que podem ser tratados ou prevenidos com os compostos, incluem a artrite reumatóide e/ou seus sintomas associados, o lupus eritematoso sistêmico e/ou seus sintomas associados e a esclerose múltipla e/ou seus sintomas associados.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49164103P | 2003-07-30 | 2003-07-30 | |
US53159803P | 2003-12-19 | 2003-12-19 | |
US57224604P | 2004-05-18 | 2004-05-18 | |
PCT/US2004/024716 WO2005016893A2 (en) | 2003-07-30 | 2004-07-30 | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0413018A true BRPI0413018A (pt) | 2006-10-03 |
BRPI0413018B1 BRPI0413018B1 (pt) | 2018-12-26 |
BRPI0413018B8 BRPI0413018B8 (pt) | 2021-05-25 |
Family
ID=34119815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0413018A BRPI0413018B8 (pt) | 2003-07-30 | 2004-07-30 | composto, e, uso de um composto |
Country Status (22)
Country | Link |
---|---|
US (10) | US7122542B2 (pt) |
EP (1) | EP1656372B1 (pt) |
JP (2) | JP4886511B2 (pt) |
KR (2) | KR101201603B1 (pt) |
CN (2) | CN1849318B (pt) |
AU (2) | AU2004265288A1 (pt) |
BR (1) | BRPI0413018B8 (pt) |
CA (1) | CA2533377C (pt) |
CY (1) | CY1114445T1 (pt) |
DK (1) | DK1656372T3 (pt) |
ES (1) | ES2421139T3 (pt) |
HK (1) | HK1091209A1 (pt) |
HR (1) | HRP20130602T1 (pt) |
IL (1) | IL173299A (pt) |
NO (1) | NO333771B1 (pt) |
NZ (1) | NZ545270A (pt) |
PL (1) | PL1656372T3 (pt) |
PT (1) | PT1656372E (pt) |
RS (1) | RS53109B (pt) |
SG (1) | SG145698A1 (pt) |
WO (2) | WO2005016893A2 (pt) |
ZA (1) | ZA200601460B (pt) |
Families Citing this family (180)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
CN1678321A (zh) | 2002-07-29 | 2005-10-05 | 里格尔药品股份有限公司 | 用2,4-嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法 |
US7122542B2 (en) | 2003-07-30 | 2006-10-17 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
JP4741491B2 (ja) * | 2003-08-07 | 2011-08-03 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 抗増殖剤としての2,4−ピリミジンジアミン化合物および使用 |
WO2005118544A2 (en) * | 2004-05-18 | 2005-12-15 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
EP1761518A1 (en) * | 2004-06-18 | 2007-03-14 | Neurosearch A/S | Novel alkyl substituted piperidine derivatives as monoamine neurotransmitter re-uptake inhibitors |
WO2006004776A1 (en) | 2004-06-29 | 2006-01-12 | Rigel Pharmaceuticals, Inc. | 4-pyrimidineamine compounds and their uses as anti-proliferative agents |
JP2008511659A (ja) * | 2004-09-01 | 2008-04-17 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 2,4−ピリミジンジアミン化合物の合成 |
AU2005289426A1 (en) * | 2004-09-27 | 2006-04-06 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
GB2420559B (en) * | 2004-11-15 | 2008-08-06 | Rigel Pharmaceuticals Inc | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
DK1814878T3 (da) * | 2004-11-24 | 2012-05-07 | Rigel Pharmaceuticals Inc | Spiro-2, 4-pyrimidindiamin-forbindelser og anvendelser deraf |
DK1856135T3 (da) * | 2005-01-19 | 2010-04-12 | Rigel Pharmaceuticals Inc | Prodrugs af 2,4-pyrimidindiamin-forbindelser og deres anvendelser |
SI2383268T1 (sl) | 2005-02-04 | 2016-02-29 | Astrazeneca Ab | Derivati pirazolilaminopiridina uporabni kot kinazni inhibitorji |
US8227455B2 (en) | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
US20060270694A1 (en) * | 2005-05-03 | 2006-11-30 | Rigel Pharmaceuticals, Inc. | JAK kinase inhibitors and their uses |
NZ563454A (en) * | 2005-06-08 | 2011-03-31 | Rigel Pharmaceuticals Inc | 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway |
US20070203161A1 (en) * | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
CA2607901C (en) | 2005-06-13 | 2016-08-16 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine |
ES2279500T3 (es) * | 2005-06-17 | 2007-08-16 | Magneti Marelli Powertrain S.P.A. | Inyector de carburante. |
US20070117775A1 (en) * | 2005-10-31 | 2007-05-24 | Rigel Pharmaceuticals, Inc. | Compositions and Methods For Treating Inflammatory Disorders |
BR122021011788B1 (pt) * | 2005-11-01 | 2022-01-25 | Impact Biomedicines, Inc | Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica |
US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US8133900B2 (en) * | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
US7713987B2 (en) * | 2005-12-06 | 2010-05-11 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2,4-diamines and their uses |
US20080318989A1 (en) * | 2005-12-19 | 2008-12-25 | Burdick Daniel J | Pyrimidine Kinase Inhibitors |
WO2007085540A1 (en) * | 2006-01-27 | 2007-08-02 | Glaxo Group Limited | 1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives |
EP1984357B1 (en) * | 2006-02-17 | 2013-10-02 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases |
US8962643B2 (en) | 2006-02-24 | 2015-02-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
AU2007257650A1 (en) * | 2006-06-15 | 2007-12-21 | Boehringer Ingelheim International Gmbh | 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase C-alpha |
KR20090023698A (ko) | 2006-06-15 | 2009-03-05 | 베링거 인겔하임 인터내셔날 게엠베하 | 2-아닐리노-4-아미노알킬렌아미노피리미딘 |
EP2089369B1 (en) | 2006-10-19 | 2011-02-02 | Rigel Pharmaceuticals, Inc. | 2,4 -pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases |
EP2222647B1 (en) | 2006-10-23 | 2015-08-05 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
EP2420505A1 (en) * | 2006-11-21 | 2012-02-22 | Rigel Pharmaceuticals, Inc. | Prodrug salts of 2, 4- pyrimidinediamine compounds and their uses |
EP1939185A1 (de) * | 2006-12-20 | 2008-07-02 | Bayer Schering Pharma Aktiengesellschaft | Neuartige Hetaryl-Phenylendiamin-Pyrimidine als Proteinkinaseinhibitoren zur Behandlung von Krebs |
DE102007010801A1 (de) | 2007-03-02 | 2008-09-04 | Bayer Cropscience Ag | Diaminopyrimidine als Fungizide |
WO2008118822A1 (en) | 2007-03-23 | 2008-10-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US7834024B2 (en) | 2007-03-26 | 2010-11-16 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US8445679B2 (en) | 2007-04-16 | 2013-05-21 | Abbvie Inc. | 7-substituted indole MCL-1 inhibitors |
AU2008275918B2 (en) | 2007-07-17 | 2014-01-30 | Rigel Pharmaceuticals, Inc. | Cyclic amine substituted pyrimidinediamines as PKC inhibitors |
MX2010002336A (es) | 2007-08-28 | 2010-03-25 | Irm Llc | Derivados de 2-bifenil-amino-4-amino-pirimidina como inhibidores de cinasa. |
US20090088371A1 (en) * | 2007-08-28 | 2009-04-02 | Rigel Pharmaceuticals, Inc. | Combination therapy with syk kinase inhibitor |
CA2697495C (en) * | 2007-09-05 | 2013-02-05 | Pfizer Limited | Xinafoate salt of n4-[(2,2-difluoro-4h-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-n2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine |
SI2265607T1 (sl) | 2008-02-15 | 2017-06-30 | Rigel Pharmaceuticals, Inc. | Spojine pirimidin-2-amina in njihova uporaba kot inhibitorji JAK kinaz |
JP5298187B2 (ja) * | 2008-04-07 | 2013-09-25 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
ES2546502T3 (es) | 2008-04-16 | 2015-09-24 | Portola Pharmaceuticals, Inc. | 2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas |
KR20170051521A (ko) | 2008-04-16 | 2017-05-11 | 포톨라 파마슈티컬스, 인코포레이티드 | syk 또는 JAK 키나제 억제제로서의 2,6-디아미노-피리미딘-5-일-카르복스아미드 |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
AU2009238590A1 (en) | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
MX2010012703A (es) | 2008-05-21 | 2010-12-21 | Ariad Pharma Inc | Derivados fosforosos como inhibidores de cinasa. |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
PE20100087A1 (es) | 2008-06-25 | 2010-02-08 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
US8445505B2 (en) | 2008-06-25 | 2013-05-21 | Irm Llc | Pyrimidine derivatives as kinase inhibitors |
WO2009158431A2 (en) * | 2008-06-25 | 2009-12-30 | Irm Llc | Compounds and compositions as kinase inhibitors |
US8450335B2 (en) * | 2008-06-27 | 2013-05-28 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
EP2161259A1 (de) | 2008-09-03 | 2010-03-10 | Bayer CropScience AG | 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide |
JPWO2010027002A1 (ja) * | 2008-09-05 | 2012-02-02 | 塩野義製薬株式会社 | Pi3k阻害活性を有する縮環モルホリン誘導体 |
EP2382210B1 (en) | 2008-12-30 | 2017-03-01 | Rigel Pharmaceuticals, Inc. | Pyrimidinediamine kinase inhibitors |
CA2749248A1 (en) * | 2009-01-14 | 2010-07-22 | Rigel Pharmaceuticals, Inc. | Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds |
CN102292333B (zh) * | 2009-01-15 | 2015-05-13 | 里格尔药品股份有限公司 | 蛋白激酶c抑制剂及其用途 |
ES2635504T3 (es) * | 2009-01-21 | 2017-10-04 | Rigel Pharmaceuticals, Inc. | Derivados de N2-(3-piridilo o fenil)-N4-(4-piperidil)-2,4-pirimidinadiamina útiles en el tratamiento de enfermedades inflamatorias, toimmunitarias o proliferativas |
PE20150621A1 (es) | 2009-01-23 | 2015-05-07 | Rigel Pharmaceuticals Inc | Derivados de 2,4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3 |
WO2010129053A2 (en) | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
TW201040162A (en) * | 2009-05-06 | 2010-11-16 | Portola Pharm Inc | Inhibitors of JAK |
UA108077C2 (xx) | 2009-07-02 | 2015-03-25 | Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну | |
JP2012533567A (ja) | 2009-07-17 | 2012-12-27 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 重水素化2,4−ピリミジンジアミン化合物およびそのプロドラッグならびにそれらの使用 |
AU2010281404A1 (en) | 2009-07-28 | 2012-02-09 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
KR101726444B1 (ko) | 2009-08-31 | 2017-04-12 | 스미또모 가가꾸 가부시키가이샤 | 수지, 레지스트 조성물 및 레지스트 패턴의 제조 방법 |
CA2780777C (en) | 2009-11-20 | 2017-12-05 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses |
US20110130415A1 (en) * | 2009-12-01 | 2011-06-02 | Rajinder Singh | Protein kinase c inhibitors and uses thereof |
EP3825316A1 (en) | 2009-12-23 | 2021-05-26 | Takeda Pharmaceutical Company Limited | Fused heteroaromatic pyrrolidinones as syk inhibitors |
WO2011103196A1 (en) * | 2010-02-17 | 2011-08-25 | Amgen Inc. | Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain |
JP6067550B2 (ja) * | 2010-04-13 | 2017-01-25 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 2,4−ピリミジンジアミン化合物およびそのプロドラッグならびにそれらの使用 |
AU2011254550B2 (en) | 2010-05-21 | 2013-11-07 | Noviga Research Ab | Novel pyrimidine derivatives |
JP5713367B2 (ja) | 2010-06-04 | 2015-05-07 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Lrrk2モジュレーターとしてのアミノピリミジン誘導体 |
US8710223B2 (en) | 2010-07-21 | 2014-04-29 | Rigel Pharmaceuticals, Inc. | Protein kinase C inhibitors and uses thereof |
TWI499581B (zh) | 2010-07-28 | 2015-09-11 | Sumitomo Chemical Co | 光阻組成物 |
ES2880622T3 (es) | 2010-07-28 | 2021-11-25 | Rigel Pharmaceuticals Inc | Composiciones y procedimientos para la inhibición de la ruta de JAK |
CN103096716B (zh) | 2010-08-10 | 2016-03-02 | 西建阿维拉米斯研究公司 | Btk抑制剂的苯磺酸盐 |
JP6195692B2 (ja) | 2010-08-30 | 2017-09-13 | 住友化学株式会社 | レジスト組成物及びレジストパターンの製造方法並びに新規化合物及び樹脂 |
JP2012102088A (ja) * | 2010-10-14 | 2012-05-31 | Sumitomo Chemical Co Ltd | ヘテロ芳香環化合物およびその有害生物防除用途 |
US10028975B2 (en) | 2010-10-19 | 2018-07-24 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating ischemia-reperfusion injury |
EP2635556B1 (en) | 2010-11-01 | 2017-06-21 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as syk modulators |
WO2012061415A1 (en) | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Oxypyrimidines as syk modulators |
WO2012061299A1 (en) | 2010-11-01 | 2012-05-10 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
WO2012061303A1 (en) | 2010-11-01 | 2012-05-10 | Avila Therapeutics, Inc. | Heteroaryl compounds and uses thereof |
EP2975027A1 (en) | 2010-11-01 | 2016-01-20 | Portola Pharmaceuticals, Inc. | Nicotinamides as jak kinase modulators |
WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
EP2637502B1 (en) | 2010-11-10 | 2018-01-10 | Celgene CAR LLC | Mutant-selective egfr inhibitors and uses thereof |
CA3017869C (en) * | 2010-11-10 | 2021-07-27 | Genentech, Inc. | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
JP5879834B2 (ja) | 2010-11-15 | 2016-03-08 | 住友化学株式会社 | 塩、レジスト組成物及びレジストパターンの製造方法 |
EP2489663A1 (en) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
JP5898521B2 (ja) | 2011-02-25 | 2016-04-06 | 住友化学株式会社 | レジスト組成物及びレジストパターンの製造方法 |
JP5947051B2 (ja) | 2011-02-25 | 2016-07-06 | 住友化学株式会社 | レジスト組成物及びレジストパターンの製造方法 |
JP5947053B2 (ja) | 2011-02-25 | 2016-07-06 | 住友化学株式会社 | レジスト組成物及びレジストパターンの製造方法 |
JP6034025B2 (ja) | 2011-02-25 | 2016-11-30 | 住友化学株式会社 | レジスト組成物及びレジストパターンの製造方法 |
JP5829939B2 (ja) | 2011-02-25 | 2015-12-09 | 住友化学株式会社 | レジスト組成物及びレジストパターンの製造方法 |
JP5829941B2 (ja) | 2011-02-25 | 2015-12-09 | 住友化学株式会社 | レジスト組成物及びレジストパターンの製造方法 |
JP5898520B2 (ja) | 2011-02-25 | 2016-04-06 | 住友化学株式会社 | レジスト組成物及びレジストパターンの製造方法 |
JP6034026B2 (ja) | 2011-02-25 | 2016-11-30 | 住友化学株式会社 | レジスト組成物及びレジストパターンの製造方法 |
JP5829940B2 (ja) | 2011-02-25 | 2015-12-09 | 住友化学株式会社 | レジスト組成物及びレジストパターンの製造方法 |
JP5886411B2 (ja) | 2011-03-24 | 2016-03-16 | ノビガ・リサーチ・エービーNoviga Research AB | 新規のピリミジン誘導体 |
AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
WO2012154518A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as syk inhibitors |
AU2012253886A1 (en) | 2011-05-10 | 2013-10-31 | Merck Sharp & Dohme Corp. | Pyridyl aminopyridines as Syk inhibitors |
MX2013013090A (es) | 2011-05-10 | 2013-12-16 | Merck Sharp & Dohme | Aminopirimidinas como inhibidores de tirosina cinaza del bazo. |
WO2012177714A1 (en) | 2011-06-22 | 2012-12-27 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
JP5996944B2 (ja) | 2011-07-19 | 2016-09-21 | 住友化学株式会社 | レジスト組成物及びレジストパターンの製造方法 |
JP5977595B2 (ja) | 2011-07-19 | 2016-08-24 | 住友化学株式会社 | レジスト組成物及びレジストパターンの製造方法 |
JP6130630B2 (ja) | 2011-07-19 | 2017-05-17 | 住友化学株式会社 | レジスト組成物及びレジストパターンの製造方法 |
JP6013798B2 (ja) | 2011-07-19 | 2016-10-25 | 住友化学株式会社 | レジスト組成物及びレジストパターンの製造方法 |
JP6013797B2 (ja) | 2011-07-19 | 2016-10-25 | 住友化学株式会社 | レジスト組成物及びレジストパターンの製造方法 |
JP5990041B2 (ja) | 2011-07-19 | 2016-09-07 | 住友化学株式会社 | レジスト組成物及びレジストパターンの製造方法 |
JP6013799B2 (ja) | 2011-07-19 | 2016-10-25 | 住友化学株式会社 | レジスト組成物及びレジストパターンの製造方法 |
JP5977593B2 (ja) | 2011-07-19 | 2016-08-24 | 住友化学株式会社 | レジスト組成物及びレジストパターンの製造方法 |
JP5886696B2 (ja) | 2011-07-19 | 2016-03-16 | 住友化学株式会社 | レジスト組成物及びレジストパターンの製造方法 |
JP6130631B2 (ja) | 2011-07-19 | 2017-05-17 | 住友化学株式会社 | レジスト組成物及びレジストパターンの製造方法 |
JP5985898B2 (ja) | 2011-07-19 | 2016-09-06 | 住友化学株式会社 | レジスト組成物及びレジストパターンの製造方法 |
JP5977594B2 (ja) | 2011-07-19 | 2016-08-24 | 住友化学株式会社 | レジスト組成物及びレジストパターンの製造方法 |
JP6189020B2 (ja) | 2011-07-19 | 2017-08-30 | 住友化学株式会社 | レジスト組成物及びレジストパターンの製造方法 |
JP5912912B2 (ja) | 2011-07-19 | 2016-04-27 | 住友化学株式会社 | レジスト組成物及びレジストパターンの製造方法 |
EA028432B1 (ru) | 2011-07-28 | 2017-11-30 | Райджел Фармасьютикалз, Инк. | Новые составы на основе (триметоксифениламино)пиримидинилов |
FI3392252T3 (fi) | 2011-08-23 | 2024-01-08 | Libertas Bio Inc | Pyrimidopyridazinoniyhdisteet ja niiden käyttö |
JP2014525418A (ja) * | 2011-09-05 | 2014-09-29 | 浙江海正薬業股▲ふん▼有限公司 | タンパク質キナーゼ阻害活性を有する4−置換−(3−置換−1h−ピラゾール−5−アミノ)−ピリミジン誘導体及びその使用 |
WO2013052391A1 (en) | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | PHENYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
WO2013052394A1 (en) | 2011-10-05 | 2013-04-11 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
US8987456B2 (en) | 2011-10-05 | 2015-03-24 | Merck Sharp & Dohme Corp. | 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors |
CA2853498A1 (en) | 2011-10-28 | 2013-05-02 | Celgene Avilomics Research, Inc. | Methods of treating a bruton's tyrosine kinase disease or disorder |
MX363551B (es) | 2011-11-23 | 2019-03-27 | Portola Pharmaceuticals Inc Star | Compuestos derivados de pirazina como inhibidores de cinasa. |
CN104254531B (zh) * | 2012-02-21 | 2017-05-03 | 默克专利股份公司 | 环状二氨基嘧啶衍生物 |
SG11201405691WA (en) | 2012-03-15 | 2014-10-30 | Celgene Avilomics Res Inc | Solid forms of an epidermal growth factor receptor kinase inhibitor |
CN104284584B (zh) | 2012-03-15 | 2019-06-04 | 西建卡尔有限责任公司 | 表皮生长因子受体激酶抑制剂的盐 |
JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Egfr発動性がんの細胞増殖阻害用化合物 |
US20130310340A1 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
EP2863913B1 (en) | 2012-06-20 | 2018-09-12 | Merck Sharp & Dohme Corp. | Imidazolyl analogs as syk inhibitors |
WO2013192125A1 (en) | 2012-06-20 | 2013-12-27 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as syk inhibitors |
WO2013192088A1 (en) | 2012-06-22 | 2013-12-27 | Merck Sharp & Dohme Corp. | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
WO2013192098A1 (en) | 2012-06-22 | 2013-12-27 | Merck Sharp & Dohme Corp. | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
KR101446742B1 (ko) | 2012-08-10 | 2014-10-01 | 한국화학연구원 | N2,n4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
US9353066B2 (en) | 2012-08-20 | 2016-05-31 | Merck Sharp & Dohme Corp. | Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors |
EP2900665B1 (en) | 2012-09-28 | 2018-01-03 | Merck Sharp & Dohme Corp. | Triazolyl derivatives as syk inhibitors |
EP2903970A4 (en) | 2012-10-08 | 2016-11-30 | Portola Pharm Inc | SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS |
EP2928891B1 (en) | 2012-12-04 | 2019-02-20 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
EP2931281B1 (en) | 2012-12-12 | 2018-01-17 | Merck Sharp & Dohme Corp. | Amino-pyrimidine-containing spleen tyrosine kinase inhibitors |
WO2014100748A1 (en) | 2012-12-21 | 2014-06-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
EP2934525B1 (en) | 2012-12-21 | 2019-05-08 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors |
JP2016506930A (ja) | 2013-01-25 | 2016-03-07 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 炎症性腸疾患を処置するための化合物および方法 |
MX2015009952A (es) | 2013-02-08 | 2015-10-05 | Celgene Avilomics Res Inc | Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos. |
EP2970275B1 (en) | 2013-03-14 | 2018-05-09 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
WO2014176216A1 (en) | 2013-04-26 | 2014-10-30 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors |
WO2014176210A1 (en) | 2013-04-26 | 2014-10-30 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
ES2701088T3 (es) | 2013-12-20 | 2019-02-20 | Rigel Pharmaceuticals Inc | Procedimiento farmacéutico y compuestos intermedios |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US9783531B2 (en) | 2013-12-20 | 2017-10-10 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
EP3083559B1 (en) | 2013-12-20 | 2021-03-10 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
US9670196B2 (en) | 2013-12-20 | 2017-06-06 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors |
WO2015138273A1 (en) | 2014-03-13 | 2015-09-17 | Merck Sharp & Dohme Corp. | 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors |
CN104926795B (zh) * | 2014-03-17 | 2017-11-10 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
CA2943979A1 (en) | 2014-03-28 | 2015-10-01 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
CN105017159B (zh) * | 2014-04-28 | 2019-05-17 | 四川大学 | 5-氟-2,4-二取代氨基嘧啶衍生物及其制备方法和用途 |
EP3179858B1 (en) | 2014-08-13 | 2019-05-15 | Celgene Car Llc | Forms and compositions of an erk inhibitor |
WO2016172053A1 (en) | 2015-04-24 | 2016-10-27 | Rigel Pharmaceuticals, Inc. | Methods of treating ibrutinib-resistant disease |
CN108137559B (zh) * | 2015-07-09 | 2021-11-02 | 默克专利有限公司 | 用作btk抑制剂的嘧啶衍生物及其用途 |
US9938257B2 (en) | 2015-09-11 | 2018-04-10 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
US10258402B2 (en) | 2016-01-04 | 2019-04-16 | OsteoCertus, LLC | Orthopedic bone plate system |
US10478237B2 (en) | 2016-01-04 | 2019-11-19 | OsteoCertus, LLC | Orthopedic bone plate system |
US10939943B2 (en) | 2016-01-04 | 2021-03-09 | OsteoCertus, LLC | Orthopedic bone plate system |
WO2017156527A1 (en) * | 2016-03-11 | 2017-09-14 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Aurora kinase and janus kinase inhibitors for prevention of graft versus host disease |
RU2621187C1 (ru) * | 2016-05-13 | 2017-06-01 | Общество с ограниченной ответственностью "Молекулярные Технологии" | Новая кристаллическая солевая форма 2,2-диметил-6-((4-((3,4,5-триметоксифенил)амино)-1,3,5-триазин-2-ил)амино)-2н-пиридо[3,2-в][1,4]оксазин-3(4н)-она для медицинского применения |
CN118105392A (zh) | 2017-04-28 | 2024-05-31 | 自由生物有限公司 | 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型 |
BR112020007679A2 (pt) | 2017-10-19 | 2020-10-20 | Bayer Animal Health Gmbh | uso de pirrolidonas heteroaromáticas fundidas para tratamento e prevenção de doenças em animais. |
PE20220597A1 (es) | 2019-05-10 | 2022-04-22 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos |
JP2022531932A (ja) | 2019-05-10 | 2022-07-12 | デシフェラ・ファーマシューティカルズ,エルエルシー | ヘテロアリールアミノピリミジンアミドオートファジー阻害剤およびその使用方法 |
WO2020243612A1 (en) | 2019-05-29 | 2020-12-03 | Rigel Pharmaceuticals, Inc. | Method of preventing and treating thrombosis |
EP3983081A1 (en) | 2019-06-17 | 2022-04-20 | Deciphera Pharmaceuticals, LLC | Aminopyrimidine amide autophagy inhibitors and methods of use thereof |
JP2022543843A (ja) | 2019-08-08 | 2022-10-14 | ライジェル ファーマシューティカルズ, インコーポレイテッド | サイトカイン放出症候群を治療するための化合物及び方法 |
EP4013420B1 (en) | 2019-08-14 | 2023-11-01 | Rigel Pharmaceuticals, Inc. | Method of blocking or ameliorating cytokine release syndrome |
Family Cites Families (265)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3159547A (en) | 1963-06-28 | 1964-12-01 | Abbott Lab | Method of lowering blood pressure with 4-(2-amino-4-pyrimidylamino)-benzene-sulfonamide |
US3320256A (en) | 1965-04-09 | 1967-05-16 | Hoffmann La Roche | Fluorinated imidazoo[1, 2-c]pyrimidines and pyrimido[1, 2-c]pyrimidines |
US4166452A (en) * | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4256108A (en) * | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4265874A (en) * | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
GR80171B (en) | 1983-08-29 | 1985-01-02 | Ciba Geigy Ag | N-(2-nitrophenyl)-4-aminopyrimidine derivatives process for the preparation thereof and use |
HU192875B (en) | 1984-10-05 | 1987-07-28 | Richter Gedeon Vegyeszet | Process for preparing 2-pyridinethiol derivatives |
DE3666587D1 (en) * | 1985-08-02 | 1989-11-30 | Leo Pharm Prod Ltd | Novel vitamin d analogues |
DE3618353A1 (de) | 1986-05-31 | 1987-12-03 | Hoechst Ag | Schaedlingsbekaempfungsmittel auf der basis von aminopyrimidin-derivaten sowie neue aminopyrimidin-verbindungen |
EP0285571B1 (de) | 1987-04-02 | 1992-02-05 | Ciba-Geigy Ag | Reaktivfarbstoffe, deren Herstellung und Verwendung |
SU1499883A1 (ru) | 1987-11-24 | 1991-10-23 | Научно-исследовательский институт фармакологии АМН СССР | Дихлоргидрат 2,4-бис-(п-трет-бутиланилино)-5-окси-6-метилпиримидина, обладающий анальгетической и противовоспалительной активностью |
JP2711161B2 (ja) * | 1988-04-21 | 1998-02-10 | レオ・ファーマシューティカル・プロダクツ・リミテッド・エイ/エス(レーベンス・ケミスケ・ファブリック・プロデュクチオンスアクチーセルスカブ) | 新規ビタミンd類似体 |
HU206337B (en) * | 1988-12-29 | 1992-10-28 | Mitsui Petrochemical Ind | Process for producing pyrimidine derivatives and pharmaceutical compositions |
US4969781A (en) * | 1989-04-07 | 1990-11-13 | The B. F. Goodrich Company | Blind fastener hand tool |
IE63502B1 (en) | 1989-04-21 | 1995-05-03 | Zeneca Ltd | Aminopyrimidine derivatives useful for treating cardiovascular disorders |
US4983608A (en) | 1989-09-05 | 1991-01-08 | Hoechst-Roussell Pharmaceuticals, Inc. | N-substituted-4-pyrimidinamines and pyrimidinediamines |
US5179204A (en) * | 1989-09-05 | 1993-01-12 | Hoechst-Roussel Pharmaceuticals Incorporated | N-substituted-4-pyrimidinamines and pyrimidinediamines |
JPH03127790A (ja) | 1989-10-11 | 1991-05-30 | Morishita Pharmaceut Co Ltd | N―(1h―テトラゾール―5―イル)―2―アニリノ―5―ピリミジンカルボキシアミド類及びその合成中間体 |
TW224941B (pt) | 1989-11-08 | 1994-06-11 | Yamanouchi Pharma Co Ltd | |
US5532228A (en) * | 1990-02-06 | 1996-07-02 | Schering Aktiengesellschaft | Side-chain homologous vitamin D derivatives, process for their production, pharmaceutical preparations containing these derivatives and their use as pharmaceutical agents |
DE4011682A1 (de) * | 1990-04-06 | 1991-10-10 | Schering Ag | 24-oxa-derivate in der vitamin d-reihe |
GB9012592D0 (en) | 1990-06-06 | 1990-07-25 | Smithkline Beecham Intercredit | Compounds |
DE4029650A1 (de) | 1990-09-19 | 1992-03-26 | Hoechst Ag | 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide |
US5246948A (en) * | 1991-05-10 | 1993-09-21 | Takeda Chemical Industries, Ltd. | Pyridine derivatives, their production and use |
US5200400A (en) * | 1991-07-12 | 1993-04-06 | New England Deaconess Hospital Corporation | Method for inhibiting allograft rejection using photoactivatable nucleotides or nucleosides |
CA2074864A1 (en) | 1991-07-30 | 1993-01-31 | Carmen Almansa | Tetralones with pharmacological activity |
US5728536A (en) | 1993-07-29 | 1998-03-17 | St. Jude Children's Research Hospital | Jak kinases and regulation of Cytokine signal transduction |
DE4141746A1 (de) * | 1991-12-13 | 1993-06-17 | Schering Ag | 20-methyl-substituierte vitamin d-derivate |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
US5194431A (en) * | 1992-07-08 | 1993-03-16 | Wisconsin Alumni Research Foundation | 24-cyclopropane vitamin D derivatives |
TW287160B (pt) | 1992-12-10 | 1996-10-01 | Hoffmann La Roche | |
EP0723533A1 (en) | 1993-10-12 | 1996-07-31 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
IL112290A (en) | 1994-01-12 | 1999-01-26 | Novartis Ag | Transformed aryl and the troiryl pyrimidines and herbicides containing them |
US5585381A (en) * | 1994-06-01 | 1996-12-17 | Kureha Chemical Industry Co., Ltd. | Pyrimidine derivatives and pharmaceutical composition |
US5733932A (en) | 1995-01-06 | 1998-03-31 | The Picower Institute For Medical Research | Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions |
US6242434B1 (en) * | 1997-08-08 | 2001-06-05 | Bone Care International, Inc. | 24-hydroxyvitamin D, analogs and uses thereof |
US6316635B1 (en) * | 1995-06-07 | 2001-11-13 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
US5700904A (en) | 1995-06-07 | 1997-12-23 | Eli Lilly And Company | Preparation of an acylated protein powder |
GB9516121D0 (en) | 1995-08-05 | 1995-10-04 | Pfizer Ltd | Organometallic addition to ketones |
AU6926596A (en) | 1995-08-24 | 1997-03-19 | Basf Aktiengesellschaft | N-heterocyclic compounds, intermediate products used to prepare them, agents containing them and their use in antifungal applications |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
JP4058129B2 (ja) * | 1996-03-18 | 2008-03-05 | 株式会社資生堂 | ピリジン誘導体及び抗潰瘍剤、抗菌剤 |
TW440563B (en) | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
US6696448B2 (en) * | 1996-06-05 | 2004-02-24 | Sugen, Inc. | 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors |
GB9619284D0 (en) | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
US6004985A (en) | 1996-10-09 | 1999-12-21 | Berlex Laboratories, Inc. | Thio acid derived monocylic N-heterocyclics as anticoagulants |
GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
US6486185B1 (en) * | 1997-05-07 | 2002-11-26 | Sugen, Inc. | 3-heteroarylidene-2-indolinone protein kinase inhibitors |
US6316429B1 (en) * | 1997-05-07 | 2001-11-13 | Sugen, Inc. | Bicyclic protein kinase inhibitors |
US6987113B2 (en) * | 1997-06-11 | 2006-01-17 | Sugen, Inc. | Tyrosine kinase inhibitors |
SE9702401D0 (sv) * | 1997-06-19 | 1997-06-19 | Astra Ab | Pharmaceutical use |
GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
US6133305A (en) * | 1997-09-26 | 2000-10-17 | Sugen, Inc. | 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity |
US6093820A (en) * | 1997-10-02 | 2000-07-25 | Taro Pharmaceutical Industries Ltd. | Method and reagents for N-alkylating ureides |
US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
GB9723859D0 (en) | 1997-11-12 | 1998-01-07 | Zeneca Ltd | Compound,composition and use |
DE19750701A1 (de) | 1997-11-15 | 1999-05-20 | Dystar Textilfarben Gmbh & Co | Verfahren zur Umsetzung von fluorsubstituierten Heterocyclen mit Aminen in Gegenwart von Phasentransfer-Katalysatoren |
EP1054004B1 (en) | 1997-12-15 | 2008-07-16 | Astellas Pharma Inc. | Novel pyrimidine-5-carboxamide derivatives |
EP1051181B1 (en) * | 1997-12-31 | 2004-03-17 | The University Of Kansas | Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof |
EP1054874B1 (en) * | 1998-02-13 | 2002-08-28 | PHARMACIA & UPJOHN COMPANY | Substituted aminophenyl isoxazoline derivatives useful as antimicrobials |
ATE245641T1 (de) | 1998-02-17 | 2003-08-15 | Tularik Inc | Antivirale pyrimidinderivate |
HU230522B1 (hu) | 1998-03-27 | 2016-10-28 | Janssen Pharmaceutica N.V | HIV-gátló pirimidinszármazékok |
BRPI9909191B8 (pt) | 1998-03-27 | 2021-07-06 | Janssen Pharmaceutica Nv | derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende |
GB9806739D0 (en) | 1998-03-28 | 1998-05-27 | Univ Newcastle Ventures Ltd | Cyclin dependent kinase inhibitors |
JP2003504301A (ja) | 1998-04-01 | 2003-02-04 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | インテグリンアンタゴニスト |
JP4472173B2 (ja) * | 1998-04-15 | 2010-06-02 | セローノ ジェネティクス インスティテュート ソシエテ アノニム | 5−リポキシゲナーゼ活性化タンパク(flap)のゲノム配列、その多型マーカーおよび喘息の検出方法 |
JP2002516322A (ja) | 1998-05-22 | 2002-06-04 | スミスクライン・ビーチャム・コーポレイション | 新規2−アルキル置換イミダゾール化合物 |
EP1091739A1 (en) | 1998-06-30 | 2001-04-18 | Parker Hughes Institute | Method for inhibiting c-jun expression using jak-3 inhibitors |
AU5682799A (en) | 1998-08-21 | 2000-03-14 | Parker Hughes Institute | Quinazoline derivatives |
JP2002523497A (ja) | 1998-08-29 | 2002-07-30 | アストラゼネカ・アクチエボラーグ | ピリミジン化合物 |
DE19851421A1 (de) | 1998-11-07 | 2000-05-11 | Boehringer Ingelheim Pharma | Neue Pyrimidine, deren Herstellung und Verwendung |
OA11674A (en) | 1998-11-10 | 2005-01-12 | Janssen Pharmaceutica Nv | HIV Replication inhibiting pyrimidines. |
JP2002529444A (ja) * | 1998-11-12 | 2002-09-10 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 二環式シグナル伝達阻害剤、それを含む組成物とその用途 |
US6127376A (en) * | 1998-12-04 | 2000-10-03 | Berlex Laboratories, Inc. | Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
US6841567B1 (en) | 1999-02-12 | 2005-01-11 | Cephalon, Inc. | Cyclic substituted fused pyrrolocarbazoles and isoindolones |
US6673908B1 (en) * | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
GB9904995D0 (en) | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Substituted aza-oxindole derivatives |
US6624171B1 (en) * | 1999-03-04 | 2003-09-23 | Smithkline Beecham Corporation | Substituted aza-oxindole derivatives |
US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
SE9901079D0 (sv) | 1999-03-23 | 1999-03-23 | Astra Ab | Novel compounds |
KR20010108394A (ko) | 1999-03-26 | 2001-12-07 | 다비드 에 질레스 | 신규 화합물 |
WO2000059893A1 (en) | 1999-04-06 | 2000-10-12 | Krenitsky Pharmaceuticals Inc. | Neurotrophic thio substituted pyrimidines |
GB9907658D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
DE19917785A1 (de) | 1999-04-20 | 2000-10-26 | Bayer Ag | 2,4-Diamino-pyrimidin-Derivate |
AU5108000A (en) | 1999-06-10 | 2001-01-02 | Yamanouchi Pharmaceutical Co., Ltd. | Novel nitrogen-contaiing heterocyclic derivatives or salts thereof |
GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
WO2001000213A1 (en) | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
TWI262914B (en) * | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
GB9918035D0 (en) | 1999-07-30 | 1999-09-29 | Novartis Ag | Organic compounds |
SK3542002A3 (en) | 1999-09-15 | 2003-04-01 | Warner Lambert Co | Pteridinones as kinase inhibitors |
OA12029A (en) | 1999-09-24 | 2006-04-28 | Janssen Pharmaceutica Nv | Antiviral compositions. |
DE19945982A1 (de) | 1999-09-24 | 2001-03-29 | Knoll Ag | Geschwindigkeitsbestimmte Partikel |
EA200200424A1 (ru) | 1999-09-30 | 2002-12-26 | Ньюроджен Корпорейшн | Некоторые гетероциклы, замещенные алкилендиамином |
KR100317935B1 (ko) | 1999-10-20 | 2001-12-22 | 유승필 | 대사성 골질환 치료용 약제조성물 및 이의 제조방법 |
GB9924862D0 (en) | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
WO2001030782A2 (en) | 1999-10-29 | 2001-05-03 | Syngenta Participations Ag | Novel herbicides |
JP2003518023A (ja) | 1999-11-30 | 2003-06-03 | パーカー ヒューズ インスティテュート | トロンビン誘導血小板凝集の阻害剤 |
JP4078074B2 (ja) | 1999-12-10 | 2008-04-23 | ファイザー・プロダクツ・インク | ピロロ[2,3−d]ピリミジン化合物 |
JP2003518123A (ja) * | 1999-12-21 | 2003-06-03 | スージェン・インコーポレーテッド | 4−置換7−アザ−インドリン−2−オンおよびその蛋白質キナーゼ阻害剤としての使用 |
ATE449764T1 (de) | 1999-12-28 | 2009-12-15 | Pharmacopeia Inc | Cytokine, insbesondere tnf-alpha, hemmer |
US20020065270A1 (en) | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
DE60129926T2 (de) | 2000-01-24 | 2008-06-19 | Genzyme Corp., Cambridge | Inhibitoren des jak/stat-weges und deren verwendung zur behandlung von allgemeiner primärer osteoarthritis |
AU782878B2 (en) * | 2000-02-05 | 2005-09-08 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of erk |
TR200103787T1 (tr) * | 2000-02-05 | 2002-10-21 | Vertex Pharmaceuticals Incorporated | Hücre-dışı sinyal ayarlı kinazların(ERK) inhibitörü olarak yararlı pirazol bileşimler |
CA2400447C (en) | 2000-02-17 | 2008-04-22 | Amgen Inc. | Kinase inhibitors |
GB0004886D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
US6525051B2 (en) | 2000-03-27 | 2003-02-25 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
US6608048B2 (en) * | 2000-03-28 | 2003-08-19 | Wyeth Holdings | Tricyclic protein kinase inhibitors |
AR028261A1 (es) | 2000-03-28 | 2003-04-30 | Wyeth Corp | Inhibidores triciclicos de la proteina quinasa |
JP4969010B2 (ja) | 2000-05-08 | 2012-07-04 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Hiv複製阻害性ピリミジンのプロドラッグ |
WO2001085700A2 (en) | 2000-05-08 | 2001-11-15 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting pyrimidines and triazines |
HUP0301114A3 (en) | 2000-06-26 | 2004-11-29 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents and pharmaceutical compositions containing them |
GB0016877D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
US20050009876A1 (en) * | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
ATE322524T1 (de) | 2000-08-18 | 2006-04-15 | 3M Innovative Properties Co | Fluoro(meth)acrylatecopolymer-beschichtungsmass n |
US6638926B2 (en) | 2000-09-15 | 2003-10-28 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
AU2001296542B2 (en) * | 2000-10-02 | 2007-10-25 | Emory University | Triptolide analogs for the treatment of autoimmune and inflammatory disorders |
US6448401B1 (en) * | 2000-11-20 | 2002-09-10 | Bristol-Myers Squibb Company | Process for water soluble azole compounds |
WO2002043735A1 (en) | 2000-11-29 | 2002-06-06 | Parker Hughes Institute | Inhibitors of thrombin induced platelet aggregation |
US20020137755A1 (en) | 2000-12-04 | 2002-09-26 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
US20020115173A1 (en) * | 2000-12-11 | 2002-08-22 | Children's Medical Center Corporation | Short peptides from the 'A-region' of protein kinases which selectively modulate protein kinase activity |
AU2002228922A1 (en) | 2000-12-12 | 2002-06-24 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
EP1349852A2 (en) * | 2000-12-20 | 2003-10-08 | Sugen, Inc. | 4-(hetero)aryl substituted indolinones |
CN100436452C (zh) | 2000-12-21 | 2008-11-26 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的吡唑化合物 |
MXPA03005696A (es) | 2000-12-21 | 2003-10-06 | Glaxo Group Ltd | Pirimidinaminas como moduladores de angiogenesis. |
AUPR279101A0 (en) * | 2001-01-30 | 2001-02-22 | Cytopia Pty Ltd | Protein kinase signalling |
JP2004528295A (ja) * | 2001-01-30 | 2004-09-16 | サイトピア ピーティワイ リミテッド | キナーゼ阻害方法 |
WO2002064096A2 (en) | 2001-02-16 | 2002-08-22 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
US7078410B2 (en) | 2001-02-20 | 2006-07-18 | Astrazeneca Ab | 2-arylamino-pyrimidines for the treatment of GSK3-related disorders |
UA75392C2 (en) | 2001-02-23 | 2006-04-17 | Merck & Co Inc | N-substituted non-aryl heterocyclic antagonists nmda/nr2b |
GB2373186A (en) | 2001-02-23 | 2002-09-18 | Astrazeneca Ab | Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation |
US20030165873A1 (en) | 2001-03-02 | 2003-09-04 | Come Jon H. | Three hybrid assay system |
PL367130A1 (en) | 2001-05-29 | 2005-02-21 | Schering Aktiengesellschaft | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
US6762179B2 (en) * | 2001-05-31 | 2004-07-13 | Vertex Pharmaceuticals Incorporated | Thiazole compounds useful as inhibitors of protein kinase |
US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
ATE339418T1 (de) | 2001-06-01 | 2006-10-15 | Vertex Pharma | Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen |
JP4541695B2 (ja) * | 2001-06-15 | 2010-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼインヒビターとしての5−(2−アミノピリミジン−4−イル)ベンズイソキサゾール |
JP2005500294A (ja) | 2001-06-19 | 2005-01-06 | ブリストル−マイヤーズ スクイブ カンパニー | ホスホジエステラーゼ7に対するピリミジン阻害剤 |
EP1408978A4 (en) | 2001-06-21 | 2005-07-13 | Ariad Pharma Inc | NOVEL PHENYLAMINO-PYRIMIDINES AND THEIR USE |
GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
MXPA03011998A (es) * | 2001-06-23 | 2005-07-01 | Aventis Pharma Inc | Pirrolopirimidinas como inhibidores de protein cinasa. |
JP4510442B2 (ja) | 2001-06-26 | 2010-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | TNF−α発現のN−ヘテロ環インヒビター |
JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
US7070996B2 (en) * | 2001-08-31 | 2006-07-04 | Rigel Pharmaceuticals, Inc. | Production of cultured human mast cells and basophils for high throughput small molecule drug discovery |
US6433018B1 (en) * | 2001-08-31 | 2002-08-13 | The Research Foundation Of State University Of New York | Method for reducing hypertrophy and ischemia |
CA2459879A1 (en) * | 2001-09-10 | 2003-03-20 | Sugen, Inc. | 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors |
WO2003030909A1 (en) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
WO2003026664A1 (en) * | 2001-09-26 | 2003-04-03 | Bayer Corporation | 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
WO2003040141A1 (en) | 2001-09-28 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders |
CA2463989C (en) | 2001-10-17 | 2012-01-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof |
WO2003032994A2 (de) | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren |
US6897208B2 (en) * | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
JP4490690B2 (ja) | 2001-11-28 | 2010-06-30 | ビーティージー・インターナショナル・リミテッド | 含窒素芳香複素環化合物を含有するアルツハイマー病の予防薬若しくは治療薬又はアミロイド蛋白線維化抑制剤 |
GT200200234A (es) | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
SE0104140D0 (sv) | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
US20030158195A1 (en) * | 2001-12-21 | 2003-08-21 | Cywin Charles L. | 1,6 naphthyridines useful as inhibitors of SYK kinase |
WO2003055489A1 (en) | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
MXPA04007191A (es) | 2002-01-23 | 2005-03-31 | Bayer Pharmaceuticals Corp | Derivados de pirimidina como inhibidores de rho-quinasa. |
TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
US6998391B2 (en) * | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
CA2476281A1 (en) | 2002-02-08 | 2003-08-14 | Smithkline Beecham Corporation | Pyrimidine compounds |
US7338959B2 (en) | 2002-03-01 | 2008-03-04 | Smithkline Beecham Corporation | Diamino-pyrimidines and their use as angiogenesis inhibitors |
US7288547B2 (en) | 2002-03-11 | 2007-10-30 | Schering Ag | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents |
WO2003076437A1 (de) | 2002-03-11 | 2003-09-18 | Schering Aktiengesellschaft | Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
AU2003231231A1 (en) | 2002-05-06 | 2003-11-11 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
AU2003301758A1 (en) | 2002-05-06 | 2004-05-25 | Bayer Pharmaceuticals Corporation | Use of pyrimidine derivates for the manifacture of a medicament for the treatment of hyper-proliferative disorders |
AR039540A1 (es) | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
CA2487679A1 (en) | 2002-05-30 | 2003-12-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of jak and cdk2 protein kinases |
CA2489458A1 (en) | 2002-06-14 | 2003-12-24 | Altana Pharma Ag | Substituted diaminopyrimidines |
CN1688553A (zh) | 2002-06-17 | 2005-10-26 | 史密丝克莱恩比彻姆公司 | 化学方法 |
JP4529685B2 (ja) | 2002-06-28 | 2010-08-25 | アステラス製薬株式会社 | ジアミノピリミジンカルボキサミド誘導体 |
US6758434B2 (en) * | 2002-07-03 | 2004-07-06 | Kimberly-Clark Worldwide, Inc. | Dispenser for multiple rolls of sheet material |
CN1678321A (zh) * | 2002-07-29 | 2005-10-05 | 里格尔药品股份有限公司 | 用2,4-嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法 |
AU2003249539A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
BR0313397A (pt) * | 2002-08-14 | 2005-06-28 | Vertex Pharmaceuticals Incorpo | Inibidores de proteina cinase e usos destes |
DE10243291B4 (de) * | 2002-09-18 | 2015-04-30 | Mann + Hummel Gmbh | Ventil, insbesondere für den Ölkreislauf einer Brennkraftmaschine |
CA2506772A1 (en) | 2002-11-01 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of jak and other protein kinases |
CA2506773A1 (en) | 2002-11-04 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Heteroaryl-pyramidine derivatives as jak inhibitors |
CA2507406A1 (en) | 2002-11-05 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of jak and other protein kinases |
GB0226583D0 (en) | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
GB0226582D0 (en) | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Anti-viral compounds |
TWI335913B (en) * | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
RU2309147C9 (ru) | 2002-11-21 | 2008-03-20 | Пфайзер Продактс Инк. | Производные 3-аминопиперидина и способы их получения |
BR0316487A (pt) | 2002-11-26 | 2005-10-11 | Pfizer Prod Inc | Método todo de tratamento da rejeição de transplantes |
US7504410B2 (en) | 2002-11-28 | 2009-03-17 | Schering Aktiengesellschaft | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
AU2002350719A1 (en) | 2002-11-29 | 2004-06-23 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
AU2003289330A1 (en) | 2002-12-13 | 2004-07-09 | Kyowa Hakko Kogyo Co., Ltd. | Preventives and/or remedies for central diseases |
DE60326646D1 (de) | 2002-12-18 | 2009-04-23 | Vertex Pharma | Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
DE602004022633D1 (de) | 2003-01-30 | 2009-10-01 | Boehringer Ingelheim Pharma | 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen |
CL2004000192A1 (es) | 2003-02-07 | 2005-03-18 | Janssen Pharmaceutica Nv | Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja. |
CL2004000303A1 (es) | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
DE602004021472D1 (en) | 2003-02-20 | 2009-07-23 | Smithkline Beecham Corp | Pyrimiidinverbindungen |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
EP1615906A1 (en) * | 2003-04-03 | 2006-01-18 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
ATE372324T1 (de) | 2003-04-30 | 2007-09-15 | Inst For Pharm Discovery Inc | Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen |
GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
US7915293B2 (en) | 2003-05-30 | 2011-03-29 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
CN1820001A (zh) | 2003-07-10 | 2006-08-16 | 神经能质公司 | 经取代的杂环二芳基胺类似物 |
EA010109B1 (ru) | 2003-07-16 | 2008-06-30 | Янссен Фармацевтика Н.В. | Триазолопиримидиновые производные в качестве ингибиторов киназы-3 гликогенсинтазы |
EP1781659B1 (en) | 2003-07-16 | 2008-11-05 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
JP2006528640A (ja) | 2003-07-22 | 2006-12-21 | ニューロジェン・コーポレーション | 置換ピリジン−2−イルアミン類縁体 |
US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
EP1651599A4 (en) | 2003-07-24 | 2008-09-24 | Merck & Co Inc | TYROSINE KINASE INHIBITORS |
US7122542B2 (en) * | 2003-07-30 | 2006-10-17 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
BRPI0412347A (pt) | 2003-07-30 | 2006-09-05 | Cyclacel Ltd | 2-aminofenil-4-fenilpiridinas como inibidores de quinase |
JP4741491B2 (ja) * | 2003-08-07 | 2011-08-03 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 抗増殖剤としての2,4−ピリミジンジアミン化合物および使用 |
MXPA06001762A (es) | 2003-08-14 | 2006-05-12 | Pfizer | Derivados de piperazina. |
JP4607879B2 (ja) | 2003-08-15 | 2011-01-05 | ノバルティス アーゲー | 新生物疾患、炎症および免疫障害の処置に有用な2,4−ピリミジンジアミン |
TWI339206B (en) | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
WO2005028467A1 (en) | 2003-09-15 | 2005-03-31 | Anadys Pharmaceuticals, Inc. | Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds |
GB0321710D0 (en) | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
AU2004272288B2 (en) | 2003-09-18 | 2008-11-13 | Novartis Ag | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
WO2005027848A2 (en) | 2003-09-19 | 2005-03-31 | Barnes-Jewish Hospital | Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators |
CN100475815C (zh) | 2003-09-25 | 2009-04-08 | 詹森药业有限公司 | 抑制hiv复制的嘌呤衍生物 |
ES2295924T3 (es) | 2003-10-03 | 2008-04-16 | Pfizer, Inc. | Derivados de tropano imidazopirina sustituidos con actividad antagonista de los receptores ccr5 para el tratamiento de vih y de la inflamacion. |
DE10349423A1 (de) * | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
PE20051046A1 (es) | 2003-11-28 | 2006-01-11 | Novartis Ag | Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina |
MY141255A (en) | 2003-12-11 | 2010-03-31 | Memory Pharm Corp | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs |
JP2007514775A (ja) | 2003-12-19 | 2007-06-07 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 1−(2,4−ピリミジンジアミノ)−2−シクロペンタンカルボキサイミド合成中間体の立体異性体および立体異性体混合物 |
MXPA06007640A (es) | 2004-01-12 | 2007-04-17 | Cytopia Res Pty Ltd | Inhibidores de quinasa selectivos. |
GB0402653D0 (en) | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
ES2424642T3 (es) | 2004-02-14 | 2013-10-07 | Irm Llc | Compuestos y composiciones como inhibidores de la proteína quinasa |
US7745625B2 (en) * | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
WO2005107760A1 (en) | 2004-04-30 | 2005-11-17 | Irm Llc | Compounds and compositions as inducers of keratinocyte differentiation |
WO2005118544A2 (en) | 2004-05-18 | 2005-12-15 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
EP1598343A1 (de) | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
US20060047135A1 (en) * | 2004-08-30 | 2006-03-02 | Chadwick Scott T | Process for preparing chloromethyl di-tert-butylphosphate |
JP2008511659A (ja) | 2004-09-01 | 2008-04-17 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 2,4−ピリミジンジアミン化合物の合成 |
EP1794134A1 (de) | 2004-09-29 | 2007-06-13 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-anilinopyrimidine als zellzyklus -kinase oder rezeptortyrosin-kinase inhibitoren, deren herstellung und verwendung als arzneimittel |
JP5162245B2 (ja) | 2004-09-30 | 2013-03-13 | テイボテク・フアーマシユーチカルズ | Hiv阻害性5−炭素環または複素環置換ピリミジン |
US7585883B2 (en) * | 2004-10-29 | 2009-09-08 | Rigel Pharmaceuticals, Inc. | Substituted pyridines and their uses |
DK1814878T3 (da) | 2004-11-24 | 2012-05-07 | Rigel Pharmaceuticals Inc | Spiro-2, 4-pyrimidindiamin-forbindelser og anvendelser deraf |
JP5208516B2 (ja) | 2004-12-30 | 2013-06-12 | エグゼリクシス, インコーポレイテッド | キナーゼモジュレーターとしてのピリミジン誘導体および使用方法 |
DK1856135T3 (da) | 2005-01-19 | 2010-04-12 | Rigel Pharmaceuticals Inc | Prodrugs af 2,4-pyrimidindiamin-forbindelser og deres anvendelser |
US20060270694A1 (en) | 2005-05-03 | 2006-11-30 | Rigel Pharmaceuticals, Inc. | JAK kinase inhibitors and their uses |
US20060251285A1 (en) | 2005-05-05 | 2006-11-09 | Mrs. Yen-Chen Chan | [surge-proof damper] |
NZ563454A (en) | 2005-06-08 | 2011-03-31 | Rigel Pharmaceuticals Inc | 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
CA2607901C (en) | 2005-06-13 | 2016-08-16 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine |
CA2614597A1 (fr) | 2005-07-11 | 2007-01-18 | Sanofi-Aventis | Nouveaux derives de 2,4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
BR122021011788B1 (pt) | 2005-11-01 | 2022-01-25 | Impact Biomedicines, Inc | Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica |
US7713987B2 (en) * | 2005-12-06 | 2010-05-11 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2,4-diamines and their uses |
BRPI0620324A2 (pt) | 2005-12-21 | 2011-11-08 | Pfizer Prod Inc | derivados de pirimidina, composição farmaceutica e uso dos mesmos |
TW200736232A (en) | 2006-01-26 | 2007-10-01 | Astrazeneca Ab | Pyrimidine derivatives |
WO2007085540A1 (en) | 2006-01-27 | 2007-08-02 | Glaxo Group Limited | 1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives |
EP1984357B1 (en) * | 2006-02-17 | 2013-10-02 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases |
US8962643B2 (en) * | 2006-02-24 | 2015-02-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
EP2089369B1 (en) | 2006-10-19 | 2011-02-02 | Rigel Pharmaceuticals, Inc. | 2,4 -pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases |
EP2420505A1 (en) * | 2006-11-21 | 2012-02-22 | Rigel Pharmaceuticals, Inc. | Prodrug salts of 2, 4- pyrimidinediamine compounds and their uses |
US20100144732A1 (en) | 2006-12-19 | 2010-06-10 | Krueger Elaine B | Pyrimidine kinase inhibitors |
TW200902010A (en) | 2007-01-26 | 2009-01-16 | Smithkline Beecham Corp | Anthranilamide inhibitors of aurora kinase |
WO2008118822A1 (en) | 2007-03-23 | 2008-10-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US7834024B2 (en) | 2007-03-26 | 2010-11-16 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
AU2008275918B2 (en) * | 2007-07-17 | 2014-01-30 | Rigel Pharmaceuticals, Inc. | Cyclic amine substituted pyrimidinediamines as PKC inhibitors |
-
2004
- 2004-07-30 US US10/903,870 patent/US7122542B2/en active Active
- 2004-07-30 NZ NZ545270A patent/NZ545270A/en unknown
- 2004-07-30 JP JP2006522105A patent/JP4886511B2/ja not_active Expired - Lifetime
- 2004-07-30 PT PT47861505T patent/PT1656372E/pt unknown
- 2004-07-30 BR BRPI0413018A patent/BRPI0413018B8/pt active IP Right Grant
- 2004-07-30 RS YU20060073A patent/RS53109B/en unknown
- 2004-07-30 SG SG200805659-0A patent/SG145698A1/en unknown
- 2004-07-30 EP EP04786150.5A patent/EP1656372B1/en not_active Expired - Lifetime
- 2004-07-30 US US10/903,263 patent/US8178671B2/en active Active
- 2004-07-30 CA CA2533377A patent/CA2533377C/en not_active Expired - Lifetime
- 2004-07-30 CN CN2004800222355A patent/CN1849318B/zh not_active Expired - Lifetime
- 2004-07-30 KR KR1020067001947A patent/KR101201603B1/ko active IP Right Grant
- 2004-07-30 CN CN2011102453252A patent/CN102358738A/zh active Pending
- 2004-07-30 PL PL04786150T patent/PL1656372T3/pl unknown
- 2004-07-30 DK DK04786150.5T patent/DK1656372T3/da active
- 2004-07-30 KR KR1020127008531A patent/KR20120062863A/ko not_active Application Discontinuation
- 2004-07-30 WO PCT/US2004/024716 patent/WO2005016893A2/en active Application Filing
- 2004-07-30 ES ES04786150T patent/ES2421139T3/es not_active Expired - Lifetime
- 2004-07-30 AU AU2004265288A patent/AU2004265288A1/en not_active Abandoned
- 2004-07-30 WO PCT/US2004/024920 patent/WO2005012294A1/en active Search and Examination
-
2006
- 2006-01-23 IL IL173299A patent/IL173299A/en active IP Right Grant
- 2006-02-23 ZA ZA2006/01460A patent/ZA200601460B/en unknown
- 2006-02-28 NO NO20060992A patent/NO333771B1/no unknown
- 2006-10-05 US US11/539,147 patent/US7452879B2/en not_active Expired - Lifetime
- 2006-10-05 US US11/539,142 patent/US7582648B2/en active Active
- 2006-10-06 US US11/539,520 patent/US7560466B2/en not_active Expired - Lifetime
- 2006-11-14 HK HK06112507.5A patent/HK1091209A1/xx not_active IP Right Cessation
-
2009
- 2009-06-18 US US12/487,486 patent/US9751893B2/en active Active
-
2011
- 2011-01-28 AU AU2011200367A patent/AU2011200367B2/en not_active Expired
- 2011-08-19 JP JP2011179459A patent/JP2011256198A/ja active Pending
-
2012
- 2012-04-09 US US13/442,480 patent/US20120253039A1/en not_active Abandoned
-
2013
- 2013-07-01 HR HRP20130602TT patent/HRP20130602T1/hr unknown
- 2013-07-09 CY CY20131100580T patent/CY1114445T1/el unknown
-
2017
- 2017-03-24 US US15/468,467 patent/US10259826B2/en not_active Expired - Lifetime
-
2019
- 2019-03-21 US US16/360,958 patent/US11230554B2/en not_active Expired - Lifetime
-
2021
- 2021-11-19 US US17/531,092 patent/US20220073536A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0413018A (pt) | composto, e, método para tratar ou prevenir doenças auto-imunes e/ou um ou mais sintomas associados com eles | |
ATE540035T1 (de) | Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen | |
NO20051069L (no) | Fremgangsmater for behandling eller hindring av autoimmunsykdommer med 2,4-pyrimidindiaminforbindelser | |
BR9915604A (pt) | Peptìdios inibidores de tgfbeta1 | |
DE69732868D1 (de) | Mittel gegen Juckreiz | |
EP1575509A4 (en) | EPHA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHOD OF USE THEREOF | |
HK1032206A1 (en) | Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function. | |
SG170813A1 (en) | New compounds | |
BR0114978A (pt) | Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares | |
NO20035025L (no) | Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet. | |
NO20010956D0 (no) | Modulering av hukommelseseffektor T-celler samt midler for dette | |
PT977716E (pt) | Utilizacao de alcoois como aditivos para rebocos e/ou argamassas | |
ES2165506T3 (es) | Antagonistas del il-8 para el tratamiento del asma. | |
BR0309684A (pt) | O tratamento de dor com ifendropil | |
PT1501505E (pt) | Utilizacao de (3-(2-etilfenil)-5-metoxifenil)-1h-1,2,4-triazole para o tratamento de doencas autoimunes | |
EA200001105A1 (ru) | 10-камфорсульфонат пароксетина для лечения нарушений цнс | |
UA4671U (uk) | Спосіб лікування і профілактики загострень ревматоїдного артриту |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/12/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/07/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |